Hepatocellular Injury in a Patient Receiving Pioglitazone
Authors: Kenji Maeda
Journal: Annals of Internal Medicine (2001)

Letters21 August 2001Hepatocellular Injury in a Patient Receiving PioglitazoneKenji Maeda, MDKenji Maeda, MDMaeda Clinic of Internal Medicine, Ageo City, Saitama Prefecture 362-0014, Japan (Maeda)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-4-200108210-00029 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Two new members of the thiazolidinedione family, rosiglitazone and pioglitazone, have been believed to be less harmful than their predecessor troglitazone. A few case reports have described possible hepatocellular injury associated with rosiglitazone (1–3), but no hepatotoxic adverse effects have been previously noted in patients treated with pioglitazone. I describe a patient who developed hepatocellular injury while taking pioglitazone (Actos, Takeda Pharmaceuticals, Osaka, Japan).A 67-year-old man with type 2 diabetes mellitus visited our outpatient clinic for a regular check-up. He was asymptomatic, but laboratory tests showed liver function abnormalities. Total bilirubin level was 10 µ mol/L ...References1. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med. 2000;132:118-21. [PMID: 10644272] LinkGoogle Scholar2. Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med. 2000;132:121-4. [PMID: 10644273] LinkGoogle Scholar3. Ravinuthala RS, Nori U. Rosiglitazone toxicity [Letter]. Ann Intern Med. 2000;133:658. [PMID: 11033603] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Maeda Clinic of Internal Medicine, Ageo City, Saitama Prefecture 362-0014, Japan (Maeda) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHepatic Failure in a Patient Taking Rosiglitazone Lisa M. Forman , David A. Simmons , and Robert H. Diamond Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report Jameela Al-Salman , Heider Arjomand , David G. Kemp , and Manoj Mittal Rosiglitazone Toxicity Ravi Sudhir Ravinuthala and Uday Nori Severe but Reversible Cholestatic Liver Injury after Pioglitazone Therapy Amar G. Pinto , Oscar W. Cummings , and Naga Chalasani Metrics Cited ByMachine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohortSevere Liver Injury Associated With High-Dose Atorvastatin TherapyNew Pioglitazone Metabolites and Absence of Opened-Ring Metabolites in New N -Substituted ThiazolidinedioneThiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and futurePrediction of drug-induced liver injury using keratinocytesEvidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in manFlagging Drugs That Inhibit the Bile Salt Export PumpThiazolidinedionesHepatotoxicity of Cardiovascular and Antidiabetic DrugsStudy on the hypoglycemic activities and metabolism of alcohol extract of Alismatis RhizomaEffect of structural modifications on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 ratsCytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cellsDrug-Induced Liver InjuryThe safety of thiazolidinedionesImportant Elements for the Diagnosis of Drug-Induced Liver InjuryInsulin releasing and alpha-glucosidase inhibitory activity of ethyl acetate fraction of Acorus calamus in vitro and in vivoMetabolism of troglitazone in hepatocytes isolated from experimentally induced diabetic ratsPioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy ReviewTreating type 2 diabetes: how safe are current therapeutic agents?INSULINS AND OTHER HYPOGLYCEMIC DRUGSRole of biotransformation in 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 ratsAssessment of genotoxicity in rats treated with the antidiabetic agent, pioglitazoneEffect of gender, dose, and time on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT)-induced hepatotoxicity in Fischer 344 ratsPractical guidelines for diagnosis and early management of drug-induced liver injuryUse of Insulin Sensitizers in NASHObesity, Inflammation, and Periodontal DiseaseThe Glitazones, Lessons so FarHepatic ToxicologyDiabetic Control AgentsThiazolidinedionesSafety and Efficacy of Low-dose Pioglitazone (7.5 mg/day) vs. Standard-dose Pioglitazone (15 mg/day) in Japanese Women with Type 2 Diabetes MellitusPioglitazoneReview article: the treatment of non-alcoholic steatohepatitis with thiazolidinedionesHepatic Injury in a Patient Taking RosiglitazoneEffect of Rosiglitazone on Serum Liver Biochemistries in Diabetic Patients with Normal and Elevated Baseline Liver EnzymesComparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazoneThiazolidinediones and InsulinNarrative Review: Hepatobiliary Disease in Type 2 Diabetes MellitusKeith G. Tolman, MD, Vivian Fonseca, MD, Meng H. Tan, MD, and Anthony Dalpiaz, PharmDAchieving Glycemic Control in Type 2 Diabetes: A Practical Guide for Clinicians on Oral HypoglycemicsSecond-Generation Thiazolidinediones and HepatotoxicityHépatite aiguë sévère à la pioglitazoneThiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factorsCombination Therapy in Type 2 DiabetesThiazolidinediones as PPAR AgonistsTreatment of PCOS with metformin and other insulin-sensitizing agentsHepatotoxicity of thiazolidinedionesThe “Glitazones”: Rosiglitazone and PioglitazoneThiazolidinediones – some recent developmentsHepatotoxicity of the thiazolidinedionesInterim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitisNephrotoxic and hepatotoxic potential of imidazolidinedione-, oxazolidinedione- and thiazolidinedione-containing analogues of N-(3,5-dichlorophenyl)succinimide (NDPS) in Fischer 344 ratsComparative Effects of Thiazolidinediones on in Vitro P450 Enzyme Induction and InhibitionInsulin SensitizersInsulin, glucagon, and hypoglycemic drugsHydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytesThe Liver, Liver Disease, and Diabetes MellitusThiazolidinediones in Type 2 Diabetes MellitusSevere but Reversible Cholestatic Liver Injury after Pioglitazone TherapyAmar G. Pinto, MD, Oscar W. Cummings, MD, and Naga Chalasani, MDCounseling Patients With Type 2 Diabetes and Insulin Resistance in the Outpatient SettingEditor's MailboxManagement of Rosiglitazone-Induced Edema: Two Case Reports and a Review of the LiteratureDrug-induced liver diseaseThiazolidinediones and type 2 diabetes: new drugs for an old diseaseMixed Hepatocellular–Cholestatic Liver Injury after Pioglitazone TherapyLouis D. May, MD, Jay H. Lefkowitch, MD, Michael T. Kram, MD, and David E. Rubin, MD“Did This Drug Cause My Patient's Hepatitis?” and Related QuestionsDavid W. Nierenberg, MDEffects of Pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical recordsGlitazones: clinical effects and molecular mechanisms 21 August 2001Volume 135, Issue 4Page: 306KeywordsAlanine aminotransferaseBilirubinLaboratory testsLiverLiver function testsOutpatient clinicsPhosphatasesSerum glutamic oxaloacetic transaminaseType 2 diabetesUltrasound imaging ePublished: 21 August 2001 Issue Published: 21 August 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...